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Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of clinicopathologic conditions ranging from steatosis alone
to nonalcoholic steatohepatitis (NASH), with varying risks for progression to cirrhosis and hepatocellular carcinoma. There is
mounting evidence that NAFLD not only complicates obesity, but also perpetuates its metabolic consequences. Critical event that
leads to progressive liver injury in NAFLD is unknown. Obesity reﬂects a generalized proinﬂammatory state with its increased
inﬂammatory markers like C reactive protein, IL-6, IL-8, IL-10, PAI-1, TNF-α, and hepatocyte growth factor. The elevated
production of these adipokines is increasingly considered to be important in the development of diseases linked to obesity and the
metabolic syndrome. Disordered cytokine production is likely to play a role in the pathogenesis of NAFLD. There is no eﬀective
treatment for NAFLD, though weight loss may halt disease progression and revert histological changes, the underlying mechanism
remaining elusive. All stages of the disease pathway from prevention, early identiﬁcation/diagnosis, and treatment require an
understanding of the pathogenesis of liver injury in NAFLD.
1.Introduction
With the rapidly growing prevalence of obesity [1] through-
out the world, morbidity and mortality related to its com-
plications is on the rise [2]. Obesity is considered a gateway
disease. Deﬁned and classiﬁed by body mass index (Table 1),
individuals with severe obesity have a disproportionately
high risk of comorbidities including nonalcoholic fatty liver
disease (NAFLD), cardiovascular disease, and diabetes [3–
6]. NAFLD now represents the most common of all liver
disordersandthemostfrequentcauseofchronicliverdisease
[7]. It is a syndrome with multifactorial aetiology with
whichobesityismostcommonlyassociated[8].Obesityitself
is typically a heterogeneous condition due to the regional
distribution of fat tissue. There is growing evidence that the
distributionofadiposetissueinthebodyisofimportancefor
the development of the metabolic complications of obesity.
Adipose tissue as an endocrine organ has become accepted
[9, 10] with the distinctive biological properties of visceral
adipose tissue presumably contributing to the increased
pathogenecity of obesity.
2.Obesityandthe Metabolic Syndrome
Metabolic syndrome or syndrome X (Tables 2(a), 2(b) and
3), is a constellation of closely related cardiovascular risk
factors characterized by obesity, insulin resistance, hyperin-
sulinemia, hyperglycaemia, dyslipidemia, and hypertension
[11–15]. Its pathological basis still remains elusive. Often
associated with insensitivity to insulin, obesity is considered
a key factor in the development of the metabolic syndrome.
In obese individuals, fatty tissue becomes insensitive to the
action of insulin resulting in greater breakdown of triglyc-
erides [16]. Overabundance of circulating free fatty acids
from excessive adiposity contributes to the development
of insulin resistance [16]. Upon reaching insulin sensitive
tissues, excessive fatty acids create insulin resistance by the
added substrate availability and by modifying downstream
signaling [16]. The release of adipose tissue-derived proteo-
hormones called adipokines also comes under the inﬂuence
of insulin. Under normal weight conditions, adipokines
guarantee homeostasis of glucose and lipid metabolism.
Theirdysregulatedproductionintheobesestateisassociated2 ISRN Gastroenterology
Table 1: WHO classiﬁcation of overweight and obesity [2].
Classiﬁcation Body mass index
(kg/m2) Associated health risks
Underweight <18.5 Low(butriskofotherclinical
problems increased)
Normal range 18.5–24.9 Average
Overweight 25.0 or higher
Pre-obese 25.0–29.9 Increased
Obese class I 30.0–34.9 Moderately increased
Obese class II 35.0–39.9 Severely increased
Obese class III 40 or higher Very severely increased
with insulin resistance and appears to play an important
role in the development of the metabolic syndrome [16,
17]. Resistance to Leptin, an important adipokine has
been suggested as an alternative concept to explain the
metabolic syndrome [16, 18]. In general, conditions like
obesity in which leptin deﬁciency or resistance are present
are associated with triglyceride accumulation in nonadipose
organs like liver, muscle, and pancreas [16, 18]. The resulting
lipotoxicity in these organs results in diabetes by causing
insulin resistance. Leptin also seems to lower insulin secre-
tion [16, 19]. Leptin resistance, however, could relate to the
hyperinsulinemia of the metabolic syndrome [16, 20].
NAFLD represents the hepatic component of the
metabolic syndrome [14, 41]. Insulin resistance is a universal
phenomenon in NAFLD [14, 42, 43] .T h ep r e s e n c eo f
metabolic syndrome carries a high risk of necroinﬂam-
mation and ﬁbrosis among NAFLD subjects and remains
strongly correlated with disease severity and progression [13,
14]. Speciﬁc adipokines may link the metabolic syndrome,
type 2 diabetes and NAFLD and an imbalance in adipokine
expression could play a pivotal role in disease progression to
NASH and cirrhosis.
3. Adipose Tissue, Adipokines,
and Inﬂammation
Fat is not uniformly distributed in the body (Table 4).
Visceral fat depots are located in the body cavity beneath
the abdominal muscles and composed of greater and lesser
omentum and the mesenteric fat [23, 25, 44]. A lesser
amount of visceral fat is located retroperitoneally [23, 25,
44]. In general, visceral fat accounts for up to 20% of
total fat in men and 5–8% in women [44]. The abdominal
subcutaneous fat is located immediately beneath the skin
and on top of the abdominal musculature [25, 44]. The
predominance of lower body fat is subcutaneous most of
which is stored in the femoral and gluteal regions [23, 44]
(Table 2).
The distribution of fat appears more important than
the total fat mass in obesity [23, 45]( Table 2). A predom-
inantly upper body fat distribution increases the risks for
the metabolic complications of obesity including hepatic
steatosis especially when it is associated with increased intra-
abdominal fat [46–49]. Most “metabolically obese” normal
Table 2: (a) International Diabetes Foundation; metabolic syn-
drome worldwide deﬁnition [15, 24]. (b) Country-/ethnicity-
speciﬁc values for waist circumference [15, 24].
(a)
Central obesity
Waist circumference∗-ethnicity speciﬁc
Plus any two of the following
Raised
triglycerides
≥1.7mmol/L (150mg/dL)
Or speccﬁc treatment for this lipid abnormality
Reduced HDL-
cholesterol
<1.03mmol/L (40mg/dL) in males
<1.29mmol/L (50mg/dL) in females
Or speciﬁc treatment for this lipid abnormality
Raised blood
pressure
Systolic: ≥130mmHg or diastolic: ≥85mmHg
Or treatment for previously diagnosed
hypertension
Raised plasma
glucose
Fasting plasma glucose ≥5.6mmol/L
(100mg/dL)
Or previously diagnosed type 2 diabetes
If above 5.6mmol or 100mg/dL
An oral glucose tolerance test is strongly
recommended but is not necessary to deﬁne the
presence of the syndrome
(b)
Country/ethnic group
Waist circumference
(cm) (as measure of
central obesity)
Europeans Male ≥94
Female ≥80
South Asians Male ≥90
Female ≥80
Chinese Male ≥90
Female ≥80
Japanese Male ≥85
Female ≥90
Table 3: The Third US National Health and Nutrition Examination
Survey (NHANES III) clinical criteria for the presence of metabolic
syndrome (presence of ≥3 criteria) [25].
Criteria Value
Abdominal obesity Waist circumference >102cm men and
>88cm women
Hypertriglyceridemia ≥150mg/dL
Low high-density
lipoprotein (HDL)
<40mg/dL in men and <50mg/dL in
women
High blood pressure ≥130/85mmHg
High fasting glucose ≥110mg/dL
weight subjects have some increase in adipose tissue mass
and insulin resistance probably due to an increase in visceral
fat [25]. Thus, subjects with a relatively low BMI can
have gross increases in abdominal visceral fat [25, 50, 51],
and others with a high BMI may have very little intra
abdominal/visceral fat [25, 52].ISRN Gastroenterology 3
Table 4: Body fat distribution [27].
Depot Remarks
Subcutaneous About 80% of all body fat. Can functionally be
divided into abdominal and gluteofemoral
Visceral
Drained by the portal vein. Anatomically divi-
ded into omental, mesenteric, and retroperi-
toneal fat
Other Peritoneal and orbital
Table 5: Regional diﬀerences in lipolysis [27, 48].
Hormone Action on lipolysis Regional diﬀerences
Catecholamines Stimulating VF > SCF abd > SCF glf
Insulin Inhibiting SCF > VF
Prostaglandins Inhibiting SCF > VF
Adenosine Inhibiting SCF > VF
VF: visceral fat; SCF: subcutaneous fat; abd: abdominal; glf: gluteofemoral.
Adipose tissue comprises of mature adipocytes, preadi-
pocytes, stromovascular cells, connective tissue matrix,
endothelial cells, sympathetic nerve ﬁbres, and macrophages
which may all contribute to adipose tissue function [26, 49,
53] In addition, it expresses numerous receptors that allow
it to respond to aﬀerent signals from traditional hormone
systems as well as the central nervous system [49]. The
cellularcompositionoffatcanvarysubstantiallyaccordingto
anatomical location and body weight. The anatomic location
of each adipose tissue depot itself aﬀects endocrine function
[25, 26, 49]. Fat mass can increase in one of two ways:
individual adipocytes can increase in volume, or they can
increase in number as more are derived from preadipocytes
[44]. Fat cell size is an important determinant of the
metabolic activity of the fat depot [45]. Visceral adipocytes
are somewhat smaller than subcutaneous cells [54–56],
though omental fat cell size does not diﬀer signiﬁcantly from
subcutaneous adipocyte [56]. Enlarged fat cells appear to
secrete increased amounts of adipokines [55, 57, 58].
The stromal vascular fraction of adipose tissue con-
tributes to the major diﬀerences between subcutaneous and
visceral fat including adipokine production. The number
of stromal vascular cells per gram of adipose tissue are
reported to be higher in omental compared to subcutaneous
fat possibly to be due to higher number of endothelial cells
in the omental fat [59]. On the other hand stromal cells
from subcutaneous fat proliferate faster than those from the
omental region [59]. Another component of adipose tissue,
the preadipocytes, has been shown by some to show greater
diﬀerentiationcapacityincaseofsubcutaneousfatcompared
to visceral adipose tissue but not by others [44, 59, 60].
The increased fat mass assumes greater signiﬁcance with
recent recognition of the adipocyte as an endocrine organ
capable of secreting a variety of bioactive peptides that
exert multiple eﬀects at both the local and systemic level
[7, 49]. To date, over ﬁfty “adipokines” have been reported
to be secreted by adipose tissue that not only inﬂuence
Table 6: Diﬀerences in adipocytokines expression between visceral
and subcutaneous fat in humans [28, 38, 49–52, 57, 63–67, 75].
Adipocytokine Diﬀerences in expression
Adiponectin VF < SCF
Adipsin VF < SCF
ASP VF < SCF
CETP VF < SCF
Leptin/Ob-Re VF < SCF
TNF-α VF = SCF
Angiotensinogen VF > SCF
Factor B VF > SCF
Il-6 VF > SCF
IL-8 VF > SCF
PAI-1 VF > SCF
PPAR-γ VF > SCF
Resistin VF > SCF
VEGF VF > SCF
11β-HSD type 1 VF > SCF
MCP-1 VF > SCF
Visfatin VF > SCF
Omentin VF > SCF
11βHSD type 1: 11-hydroxy-steroid-dehydrogenase type 1; ASP: acyla-
tion stimulation protein; CETP: cholesterol ester transfer protein; IL-6:
interleukin-6; IL-8: interleukin-8; PAI-1: plasminogen activator inhibitor-1;
PPAR-γ: peroxisome proliferators-activated receptor-γ; SCF: subcutaneous
fat; TNF-α:t u m o u rn e c r o s i sf a c t o r - α; VF: visceral fat; VEGF, vascular
endothelial growth factor; MCP-1: monocyte chemoattractant protein-1.
body weight homeostasis but also inﬂammation, coagula-
tion, ﬁbrinolysis, insulin resistance, diabetes, atherosclerosis,
and some forms of cancer [53, 61]. These include leptin,
adiponectin, resistin, acylation stimulating protein, TNF-α,
TGF-β, plasminogen activator inhibitor, angiotensin II, and
interleukins 6, 8, 10 [49, 53]t on a m eaf e w .
The vascular anatomy and metabolic activity of fat
from various depots diﬀer in a way that may explain
the association of visceral but not subcutaneous fat with
obesity-related cardiovascular and metabolic problems [23,
25, 46, 58, 62]( T a b l e s5 and 6). Regional diﬀerences are
pronounced between omental and subcutaneous fat depots
[26–29, 53]. The venous drainage of visceral fat is via
the portal system, directly providing free fatty acids as a
substrate for hepatic lipoprotein metabolism and glucose
production [23, 30, 45, 48]. Visceral omental fat has a higher
rate of lipid turn over than subcutaneous fat [30, 63, 64]
and omental adipocytes have higher basal and adrenaline-
stimulated levels of intracellular cAMP [30, 65] being more
responsive to the lipolytic eﬀects of catecholamines [31, 64,
66], and less responsive to the antilipolytic eﬀects of insulin
[30, 64, 67, 68]. Omental adipocytes express higher levels
of glucocorticoid receptors [25, 30, 69], and in very obese
individuals express lower levels of lipoprotein lipase protein
and mRNA than do subcutaneous adipocytes [30, 70].
Expression of IL-6, IL-8, resistin, PAI-1, MCP-1, and Visfatin
is relatively greater in visceral fat compared to subcutaneous
fat, whereas leptin, adiponectin, and adipsin are greater in4 ISRN Gastroenterology
Table 7: Grading and Staging of NAFLD [79, 90, 92].
Grading NAFLD
(1) Macrovesicular steatosis
Grade 0: None
G r a d e1 :U pt o3 3 %
Grade 2: 33%–66%
Grade 3: >66%
(2 ) Necroinﬂammatory activity
Grade 1 (mild) Steatosisupto66%,occasionalballoonedhepatocyte(mainlyzone3),scatteredintra-acinarneutrophils
± lymphocytes, no or mild portal inﬂammation
Grade 2 (moderate) Steatosis of any degree, obvious zone 3 ballooning degeneration, intra-acinar neutrophils, zone 3
perisinusoidal ﬁbrosis may be present, mild to moderate, portal and intra-acinar inﬂammation
Grade 3 (severe) Pan-acinar steatosis, widespread ballooning, intra-acinar inﬂammation, neutrophils associated with
ballooned hepatocytes, mild to moderate portal inﬂammation
Staging NAFLD
(1) Stage 1 Zone 3 perisinusoidal/pericellular ﬁbrosis; focally or extensively present
(2) Stage 2 Zone 3 perisinusoidal/pericellular ﬁbrosis with focal or extensive periportal ﬁbrosis
(3) Stage 3 Zone 3 perisinusoidal/pericellular ﬁbrosis and portal ﬁbrosis with focal or extensive bridging ﬁbrosis
(4) Stage 4 Cirrhosis
subcutaneous adipose tissue [26, 30–36, 49, 57, 71]. There
is no important regional variation of TNF-α production
[25, 31, 71].
Taken as a whole, these observations suggest that visceral
adipocytes may represent a specialised adipocyte population
designed to release nutrients rapidly in conditions of stress.
Obesity has been characterized by a state of chronic
low- grade inﬂammation [72, 73]. The basis of this view
is an increased circulating level of several inﬂammatory
markers in the obese including CRP, TNF-α, IL-6, IL-8, IL-
18, MIF, haptoglobin, SAA, and PAI-1 [72, 74–76]. The
inﬂammatory state may be causal in the development of
insulin resistance and the metabolic syndrome [72, 76]. It
remains unclear as to the extent to which adipose tissue
contributes quantitatively to the elevated circulating levels
of these factors and whether there is a generalised or local
state of inﬂammation [72]. The increased production of
adipokines and acute-phase proteins in obesity is considered
to be primarily related to local events within the expanding
fat depots [72]. With increasing evidence of the inﬁltration
of adipose tissue by macrophages the nonadipocyte fraction
may be a signiﬁcant component of the inﬂammatory state
withinthefattissue[77,78].Whythesecretionofadipokines
and other inﬂammation-related proteins from adipose tissue
rises sharply with increasing adiposity remains obscure.
It has been proposed that relative hypoxia of clusters of
adipocytes within an expanding adipose tissue mass triggers
the inﬂammatory response [72].
4. Nonalcoholic FattyLiverDisease (NAFLD)
Nonalcoholic fatty liver disease is a form of chronic liver
disease histologically indistinguishable from alcoholic hep-
atitis occurring in individuals without signiﬁcant alcohol
consumption [79, 80]. NAFLD comprises a morphologic
spectrum of liver lesions (Table 1) ranging from steatosis
alone to nonalcoholic steatohepatitis (NASH), with varying
risks for progression to cirrhosis [38, 79, 81]. Whereas
nonalcoholic steatosis without necroinﬂammatory change
is generally a benign condition, NASH deﬁnes the turning
point in the progression of NAFLD from steatosis to
advancedﬁbrosisandcirrhosis[8].NASHischaracterizedby
hepatocellular steatosis, necroinﬂammation, hepatocellular
injury, and pericellular or perisinusoidal ﬁbrosis [7, 82]. Iso-
lated portal inﬂammation/ﬁbrosis (IPF) signiﬁes a subset of
individuals with NAFLD who have portal ﬁbrosis associated
with hepatic steatosis in the absence of zone 3 hepatocellular
injuries [83–89]. It is thought to mark the onset of disease
progression [90].
5. Histological Criteriafor Diagnosis
The principal histologic feature of NAFLD is the presence
of macrovesicular fatty change in hepatocytes with displace-
ment of the nucleus to the edge of the cell wall [38, 39, 91].
Additional features present variably are Mallory bodies, bal-
looning degeneration, predominantly lobular neutrophilic
inﬂammation, and zone III perisinusoidal ﬁbrosis [38, 39,
91]. In many cases, atypical features like predominantly
lymphocytic inﬂammation and/or portal ﬁbrosis may be
seen [38, 39, 91].
6. HistoricalPerspectivesandPrevalence
In the 1970s, fatty liver hepatitis was noticed to aﬀect
morbidly obese patients who had undergone jejunoileal
bypass [92]. This was recognised as a new disease entity by
Ludwig who in 1980 coined the term nonalcoholicsteatohep-
atitis (NASH) for it. [93]. Later histopathological changes
consistent with the diﬀerent grades of NAFLD were reportedISRN Gastroenterology 5
with certain drugs including steroids, amiodarone, and
isoniazid [94–96]( Table 7). Increasingly, this entity has been
expanded by its recognition as an important diﬀerential in
thediagnosisofabnormalliverenzymes[97].Theprevalence
of NAFLD/NASH appears to parallel the degree of obesity
[7, 79, 80, 82, 98].The prevalence of simple steatosis in obese
patients is 70–100%, whereas NASH is found in 20–25% and
2-3% have cirrhosis [88, 89, 99–101]. The prevalence of IPF
is approximately 29% [12, 14, 24, 27–29, 62]. Many patients
with cryptogenic cirrhosis have metabolic risk factors for
NAFLD and are likely to represent cases of previously
unrecognised NAFLD [102, 103]. In cirrhosis, both steatosis
andinﬂammatorychangesmayhavedisappearedmakingthe
cause diﬃcult to establish [11, 38, 39].
7.Pathophysiology
The liver plays a central role in lipid metabolism, importing
serum-free fatty acids (FFA) and manufacturing, storing,
and exporting lipids and lipoproteins. However, the patho-
physiology that leads to NAFLD is not well understood;
in particular, the factors that lead to progressive hepa-
tocellular damage after triglyceride accumulation are not
well elucidated. The two metabolic abnormalities most
strongly associated with NAFLD are insulin resistance and
an increased supply of fatty acids to the liver [104].
The “two- hit” hypothesis remains the leading theory
of the pathogenesis of NAFLD [105, 106]. The “ﬁrst hit,”
insulin resistance, leads to steatosis as a consequence to the
alterations in lipid metabolism [105, 106]. Insulin resistance
results in increased FFA release from the fat stores. Hepatic
FFA activity is largely uncontrolled and therefore directly
proportional to plasma FFA concentrations. In the liver,
FFA can either be oxidised to generate ATP or esteriﬁed to
produce triglycerides which can be stored or incorporated
into very low density lipoproteins for export. Defects in
either of these two pathways could lead to hepatic steatosis.
Hepatic lipid accumulation does not universally result in
liver injury indicating that additional secondary insults are
important [105]. Progression to inﬂammation and ﬁbrosis
appears from oxidative stress, the “second hit,” triggered
by the accumulation of fatty acids producing more oxidant
substances than the antioxidant processes of the liver can
handle [105, 106]. Lipid peroxidation and liver damage may
beinﬂuencedbyavarietyoffactorssuchascytochromeP450
2E1 induction, endotoxin, hepatic iron, Kupﬀer cell dysfunc-
tion, and mitochondria changes and ATP homeostasis [38,
105]. Insulin resistance can contribute to all these pathways.
Portal inﬂammation appears to mark the occurrence of this
“second hit” [90]. Alterations in the adipokines resistin,
leptin,adiponectin,andTNF-αarethoughtalsotoplayarole
in the pathogenesis [11, 38] of NAFLD.
8. DiagnosisandAssessment of Severity
Most patients with NAFLD are asymptomatic, and typically
patientsarefoundincidentallytohaveabnormalbiochemical
liver function tests or hepatomegaly when evaluated for
another condition [107, 108]. A percentage of patients
present with ill-deﬁned symptoms of right upper quadrant
pain, abdominal discomfort, fatigue, or malaise [40, 97, 109,
110]. Laboratory tests are nonspeciﬁc. Most patients have
a moderate elevation in transaminases, and the ALT/AST
ratio is usually less than one [108] .Av a r i a b l ee l e v a t i o no f
alkaline phosphatase and gammaglutamyl transpeptidase is
frequent [108]. Unexplained persistent elevation of ALT is
most commonly due to NAFLD once hepatitis C and other
chronic liver diseases have been excluded, [91, 111]. Up to
50% have diabetes or glucose intolerance and up to 80%
may reveal fasting hypertriglyceridemia [93, 109, 112, 113].
An increase of iron in the liver accompanied by an elevated
saturation of transferrin and serum ferritin may be present
[109]. Antinuclear antibodies have been noted in 10%–25%
ofNAFLDpatients,thesigniﬁcanceofwhichremainsunclear
[93, 114, 115].
Imaging studies including ultrasonography, CT scan-
ning, and MRI are useful in demonstrating hepatic steatosis,
at least when fat accumulation is moderate to severe [116–
119]. However, these tests may underestimate less severe
steatosis and cannot detect the diﬀerences between NASH
and nonprogressive NAFLD [118–122] Liver biopsy remains
the gold standard in the diagnosis and staging of NAFLD
[7, 82]. It is the only diagnostic test that reliably identiﬁes
and quantiﬁes hepatic steatosis, inﬂammation, necrosis,
and ﬁbrosis; and thereby estimates prognosis and disease
progression [8, 120, 123–125]. It is recommended during
bariatric surgery to assess the extent of liver damage, the
behaviour of liver architecture after weight loss, and the
relevance of NASH in the evolution to cirrhosis [126,
127]. In addition to conﬁrming the clinical diagnosis, liver
biopsy is valuable for excluding other liver disease and for
monitoring treatment eﬃcacy [82, 128, 129]. Disadvantages
to biopsy include observer variability, sampling variation,
and morbidity and mortality [130].
To date, few investigations have speciﬁcally addressed
sampling errorandvariability inNASH.Sampling variability
has the potential to signiﬁcantly alter disease grade and
stage. The histological ﬁndings of NAFLD are usually
presumed to be homogenously distributed throughout the
liver. Consequently, in clinical practice, a single random core
biopsy is usually considered representative of overall hepatic
involvement. However, there are no data to support these
assumptions in NASH [131].
Broadly, two diﬀerent types of liver biopsy techniques are
in use: core (needle) biopsy and wedge biopsy. Needle biopsy
can be obtained percutaneously either blindly or under
radiological or ultrasound guidance and by transjugular
catheter [130, 132, 133]. Both types of biopsies can be
taken during laparoscopic or open surgery [130, 132–134].
Core biopsy has declined considerably at laparotomy or
laparoscopy and is now used mainly when focal lesions are
discoveredduringroutinesurgery[133].Wedgebiopsyofthe
liveryieldsmoreaccuratediagnosisofliverdiseasesthandoes
needle biopsy, but is more invasive and haemostasis more
problematic [135].
Types of biopsy needles include: the Tru-Cut, which is
a cutting needle, and the Menghini needle, which uses a
suction technique [132, 133, 136]. The cutting needle usually6 ISRN Gastroenterology
produces a larger sample, but is associated with a higher risk
of complications. A suction needle tends to produce more
fragmented samples [132, 137]. The size of the specimen
varies depending on the size of needle: a biopsy obtained
with 14-gauge(G) to 21G needle is usually deﬁned as large,
whereas needles less than 21G result in thin or ﬁne biopsy
samples with a core less than 1mm in diameter. The size
of the biopsy specimen that varies between 1 and 3cm in
length and between 1.2 and 2mm in diameter represents
1/50,000 to 1/100,000th of the total mass of the liver [130,
132, 133]. The traditional assumption that a sample 1.5cm
long or containing four to six portal tracts, or both, is
adequate is no longer true for the grading and staging of
chronic liver disease. Studies show that smaller samples
signiﬁcantly underestimate the disease severity and samples
at least 2cm long can ensure greater diagnostic accuracy
[133, 138].
In NAFLD, the distinction between steatosis and steato-
hepatitis and the assessment of the severity rely entirely
on liver histology. Small unrepresentative samples in the
context of uneven distribution of lesions can result in
substantial misdiagnosis and staging inaccuracies. In addi-
tion, important pathology can be overlooked if only a
single biopsy specimen is taken. It is suggested that three
consecutive specimens may improve the diagnostic yield of
liver biopsy [139]. While sampling error has been studied
fairly extensively in cases of needle biopsy, this is not true
in cases of wedge liver biopsy especially in the context of
NASH.
9. Progressionof LiverDisease
Knowledge about the natural history of NAFLD is still
evolving. There are several distinct histologic states that
indicateprogressionofthelesion:fattyliveralone,steatohep-
atitis, steatohepatitis with ﬁbrosis, and eventually cirrhosis
[91, 97]. The precise risk of mortality in patients with
NAFLD is not known. Preliminary studies suggest a more
benign course for simple steatosis and the mortality remains
low, although some have shown occasional progression to
cirrhosis [38, 40, 140]. Cross-sectional series have shown
that 30–40% of patients with NASH have advanced liver
ﬁbrosis at the time of presentation [91, 97, 141], whereas
10–15% may have established cirrhosis [7, 109, 141]. The
risk for developing increased ﬁbrosis in NASH over 5 years
is 25% and for developing cirrhosis is 15% [38, 97, 142].
The 5- and-10 year survival in NASH has been estimated
at 67% and 59% respectively, although death may arise
from comorbid conditions [38, 143]. NAFLD is a leading
cause of “cryptogenic cirrhosis” in which aetiologically
speciﬁc clinical, laboratory, or pathological features can
no longer be identiﬁed [102, 144, 145]. NAFLD-associated
cirrhosis can develop into subacute liver failure, progress
to hepatocellular carcinoma, and recur posttransplantation
[125, 144, 146]. Thus, it appears that NAFLD is associated
with the entire spectrum of chronic liver disease: progressive
ﬁbrosis, cirrhosis, end-stage liver disease, and hepatocellular
carcinoma. A number of risk factors have been identiﬁed as
predictors for progressive ﬁbrosis and cirrhosis in NAFLD
including; BMI > 30, type II diabetes, age > 45 years, and
an ALT: AST ratio > 1[ 7].
Histologicimprovementmayalsooccurwithweightloss,
especially in those with only minimal ﬁbrosis [147]. This is
particularly true when weight loss is achieved slowly [147,
148]. Rapid weight loss has been noted to accelerate disease
progression [101, 149, 150]. Liver failure becomes manifest
in many cases during a period of rapid weight loss regardless
of its mechanism [101, 149, 151].
It is clear that patients with NAFLD and even more so
with NASH have a serious liver disease with a ﬁbrogenic
potential that can result in liver-related morbidity and
mortality.
10. Visceral FatandNAFLD
Despite the high prevalence of NAFLD and its potential
for serious sequelae, the underlying aetiological factors
that determine disease progression from simple steatosis
to NASH and cirrhosis remain poorly understood. Dis-
ordered adipokine production is likely to play a role in
the pathogenesis of NAFLD [106, 152]. Adipokines are
implicated in the pathogenesis of NAFLD/NASH through
their metabolic and pro-/anti-inﬂammatory activity [153].
The literature reveals quantitative and qualitative diﬀerences
in the repertoires of mediators that are released from
peripheral and visceral fat depots [154, 155]( Table 6).
The net adipokine proﬁle generated by visceral fat appears
more noxious than that of subcutaneous fat [60]. Hence,
visceral adiposity accompanies the metabolic syndrome [60,
154]. Increasing visceral obesity is thought to result in
increased production of proinﬂammatory cytokines and
adipokines [tumour necrosis factor alpha, interleukin 6, and
C reactive protein][26, 156–158] and decreased production
of protective adipokines [adiponectin][28, 153, 156]. This
abnormal balance might ultimately lead to the clinical and
histopathological occurrence of NASH.
The exact role of adipokines in the pathogenesis of
NAFLD, however, remains investigative. Literature reveals
variable results about alteration in leptin [159–161],
adiponectin, and TNF-α [153, 162] while the role of resistin
in NAFLD in humans still awaits to be examined [162–
164] though increased resistin levels have been correlated
with NAFLD severity and NASH development [165, 166].
Investigators have shown a direct dose-dependent link
between increasing amounts of visceral fat and end-organ
tissue inﬂammation and ﬁbrosis in patients with NAFLD
demonstrating visceral fat to be directly associated with
liver inﬂammation and scarring in the metabolic syndrome
[166, 167]. Importantly, this eﬀect was independent of levels
of hepatic steatosis, patient age, and insulin resistance [166,
167]. Ethnic diﬀerences in visceral fat are being investigated
as potential links to understanding diﬀerences in NAFLD.
Compared to Caucasians, lowerlevels ofhepatic triglycerides
have been found in African Americans despite similar total
body adiposity and insulin resistance [166, 168], whilst
Asians have increased visceral fat depots in relation to their
body mass index (BMI) risking NAFLD despite low BMI
[166, 169].ISRN Gastroenterology 7
11. Conclusion
The growing epidemic of obesity across the globe constitutes
a major challenge to health services. Nonalcoholic fatty liver
disease (NAFLD) has become the most common of all liver
disorders with prevalence paralleling the degree of obesity.
A clear understanding of the mechanisms underlying disease
progression is urgently required to develop prevention and
treatment strategies. Adipokines secreted by adipose tissue
have recently been implicated in initiating and perpetuating
the chronic inﬂammatory state observed in obesity and
NAFLD. Studies should be undertaken to examine the exact
role of adipokines derived from intra-abdominal fat as these
appear to be the main drivers for the development of
progressive liver injury in patients with severe obesity.
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